Thrombosis Risk Assessment In The COVID-19 Era
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista Ciências em Saúde |
Texto Completo: | https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1006 |
Resumo: | The appearance of the coronavirus pandemic has prompted a renewed interest in thrombosis risk assessment, particularly since this disease is associated with a high risk of thrombotic events. It is known that the number one preventable cause of death in hospitalized patients including those having surgical procedures is fatal pulmonary emboli. There is also high-quality data that the use of anticoagulant drugs in the proper dose, and for the period of time shown to be efficacious, will prevent most fatal events. It is true that even with the use of the best anticoagulant regimes venous thromboembolic events (VTE) can still occur but are rarely fatal. We also realize that providing adequate anticoagulant prophylaxis for the entire period of risk is the key to preventing these deaths. Thrombosis risk scoring identifies who's at risk for these emboli and guides physician choices for appropriate preventive measures. |
id |
RCS_393dc850ce494d6363d2bfd6660a0bfd |
---|---|
oai_identifier_str |
oai:ojs.portalrcs.hcitajuba.org.br:article/1006 |
network_acronym_str |
RCS |
network_name_str |
Revista Ciências em Saúde |
repository_id_str |
|
spelling |
Thrombosis Risk Assessment In The COVID-19 EraCOVID-19tromboembolismRisk AssessmentThe appearance of the coronavirus pandemic has prompted a renewed interest in thrombosis risk assessment, particularly since this disease is associated with a high risk of thrombotic events. It is known that the number one preventable cause of death in hospitalized patients including those having surgical procedures is fatal pulmonary emboli. There is also high-quality data that the use of anticoagulant drugs in the proper dose, and for the period of time shown to be efficacious, will prevent most fatal events. It is true that even with the use of the best anticoagulant regimes venous thromboembolic events (VTE) can still occur but are rarely fatal. We also realize that providing adequate anticoagulant prophylaxis for the entire period of risk is the key to preventing these deaths. Thrombosis risk scoring identifies who's at risk for these emboli and guides physician choices for appropriate preventive measures.AISI/HCI2020-06-23info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionInvited articleArtigo de convidadotextoinfo:eu-repo/semantics/otherapplication/pdftext/xmlhttps://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/100610.21876/rcshci.v10i3.1006Revista Ciências em Saúde; v. 10 n. 3 (2020): Julho a Setembro de 2020; 1-2Health Sciences Journal; Vol 10 No 3 (2020): July to September 2020; 1-22236-378510.21876/rcshci.v10i3reponame:Revista Ciências em Saúdeinstname:Hospital de Clínicas de Itajubáinstacron:HCIenghttps://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1006/545https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1006/574Copyright (c) 2020 REVISTA CIÊNCIAS EM SAÚDEhttps://creativecommons.org/licenses/by-nc-sa/4.0info:eu-repo/semantics/openAccessCaprini, Joseph A2020-11-25T14:30:44Zoai:ojs.portalrcs.hcitajuba.org.br:article/1006Revistahttps://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zeroPUBhttps://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/oaircs@hcitajuba.org.br||rcsfmit@medicinaitajuba.com.br2236-37852236-3785opendoar:2020-11-25T14:30:44Revista Ciências em Saúde - Hospital de Clínicas de Itajubáfalse |
dc.title.none.fl_str_mv |
Thrombosis Risk Assessment In The COVID-19 Era |
title |
Thrombosis Risk Assessment In The COVID-19 Era |
spellingShingle |
Thrombosis Risk Assessment In The COVID-19 Era Caprini, Joseph A COVID-19 tromboembolism Risk Assessment |
title_short |
Thrombosis Risk Assessment In The COVID-19 Era |
title_full |
Thrombosis Risk Assessment In The COVID-19 Era |
title_fullStr |
Thrombosis Risk Assessment In The COVID-19 Era |
title_full_unstemmed |
Thrombosis Risk Assessment In The COVID-19 Era |
title_sort |
Thrombosis Risk Assessment In The COVID-19 Era |
author |
Caprini, Joseph A |
author_facet |
Caprini, Joseph A |
author_role |
author |
dc.contributor.author.fl_str_mv |
Caprini, Joseph A |
dc.subject.por.fl_str_mv |
COVID-19 tromboembolism Risk Assessment |
topic |
COVID-19 tromboembolism Risk Assessment |
description |
The appearance of the coronavirus pandemic has prompted a renewed interest in thrombosis risk assessment, particularly since this disease is associated with a high risk of thrombotic events. It is known that the number one preventable cause of death in hospitalized patients including those having surgical procedures is fatal pulmonary emboli. There is also high-quality data that the use of anticoagulant drugs in the proper dose, and for the period of time shown to be efficacious, will prevent most fatal events. It is true that even with the use of the best anticoagulant regimes venous thromboembolic events (VTE) can still occur but are rarely fatal. We also realize that providing adequate anticoagulant prophylaxis for the entire period of risk is the key to preventing these deaths. Thrombosis risk scoring identifies who's at risk for these emboli and guides physician choices for appropriate preventive measures. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-06-23 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Invited article Artigo de convidado texto info:eu-repo/semantics/other |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1006 10.21876/rcshci.v10i3.1006 |
url |
https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1006 |
identifier_str_mv |
10.21876/rcshci.v10i3.1006 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1006/545 https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1006/574 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2020 REVISTA CIÊNCIAS EM SAÚDE https://creativecommons.org/licenses/by-nc-sa/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2020 REVISTA CIÊNCIAS EM SAÚDE https://creativecommons.org/licenses/by-nc-sa/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf text/xml |
dc.publisher.none.fl_str_mv |
AISI/HCI |
publisher.none.fl_str_mv |
AISI/HCI |
dc.source.none.fl_str_mv |
Revista Ciências em Saúde; v. 10 n. 3 (2020): Julho a Setembro de 2020; 1-2 Health Sciences Journal; Vol 10 No 3 (2020): July to September 2020; 1-2 2236-3785 10.21876/rcshci.v10i3 reponame:Revista Ciências em Saúde instname:Hospital de Clínicas de Itajubá instacron:HCI |
instname_str |
Hospital de Clínicas de Itajubá |
instacron_str |
HCI |
institution |
HCI |
reponame_str |
Revista Ciências em Saúde |
collection |
Revista Ciências em Saúde |
repository.name.fl_str_mv |
Revista Ciências em Saúde - Hospital de Clínicas de Itajubá |
repository.mail.fl_str_mv |
rcs@hcitajuba.org.br||rcsfmit@medicinaitajuba.com.br |
_version_ |
1754840346495287296 |